| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
The Oncology Institute, Inc. Common Stock$5.03
+0.05 (+1%)
Market Cap
304.42 M
EPS
-0.56
P/E Ratio
-5.47 $
Value Trade
5.81 M
SEC Financials
Q1 2026Dilution Risk
Revenue
147.44 M
Operating CF
-2.21 M
Total Assets
168.23 M
Total Liabilities
184.51 M
Equity
-16.29 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
30.28 M
Monthly Burn
738.00 K
Runway
39.6 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.16 M
52 Week Range
1.80 - 4.88
% held by Insiders
36.4 %
% held by Institutions
35.56 %
Enterprise Value
374.61 M
Total Shares
98.43 M
Short %
7.87 %
Float Shares
81.60 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TOI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
The Oncology Institute, Inc. Common Stock (TOI) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
TOI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TOI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TOI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TOI Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
TOI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-TOI
May 7, 2026The Oncology Institute Reports First Quarter 2026 Financial Results
The Oncology Institute (NASDAQ: TOI) reported strong financial results for the first quarter of 2026, showcasing a remarkable 41% revenue growth compared to the same period last year. This growth was attributed to increased capitated revenue and strong performance in the pharmacy sector. Notably, the company reached profitability in Florida, indicating successful maturation of its capitated relationships. TOI plans to launch a new provider portal to enhance patient care and maintain momentum, while reaffirming its 2026 financial guidance.
Read more →-TOI
Mar 12, 2026The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026
The Oncology Institute, Inc. (NASDAQ: TOI) has reported its financial results for the fourth quarter and full year 2025, indicating solid operational progress. For 2026, the company anticipates revenues of $630 to $650 million and aims for positive Adjusted EBITDA after encountering seasonal and pricing challenges early in the year. CEO Daniel Virnich highlighted a continued focus on executing strategic initiatives and expanding the business model, whilst acknowledging various risks that could affect future performance.
Read more →-TOI
Feb 23, 2026The Oncology Institute Appoints Kim Tzoumakas to Board of Directors
The Oncology Institute, Inc. (TOI) has appointed Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Tzoumakas brings over twenty years of experience in oncology and healthcare, notably as CEO of VytlOne National Pharmacy Services and 21st Century Oncology. Her extensive background is expected to contribute significantly to TOI's expanding care delivery model and pharmacy business. The CEO of TOI expressed enthusiasm for Tzoumakas' appointment, citing her proven track record in enhancing patient care and operational efficiency.
Read more →-TOI
Jan 12, 2026The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook
The Oncology Institute (NASDAQ: TOI) has reaffirmed its 2025 guidance while providing a preliminary outlook for 2026, expecting total revenues between $630 million to $650 million. This reflects a 28% growth driven by expanded delegated contracts and strong performance in the Dispensary segment. Notably, 2026 is projected to be TOI's first year of Adjusted EBITDA profitability since going public, though the company acknowledges potential uncertainties that may affect its financial projections. Looking beyond 2026, TOI aims for continued growth in revenue and expanding margins through enhanced operational efficiency.
Read more →-TOI
Jan 5, 2026The Oncology Institute Announces Addition of Board Member Mark Stolper
The Oncology Institute (TOI) announced the appointment of Mark Stolper to its Board of Directors, effective January 2, 2026. Stolper, the CFO of RadNet, Inc., brings extensive experience in public company management and the oncology sector. His involvement is anticipated to enhance TOI's financial strategy and capital markets approach, further supporting the company's mission in cancer care. The announcement reflects TOI's commitment to addressing the financial challenges faced by cancer patients while aiming for growth in the health care sector.
Read more →-TOI
Dec 1, 2025The Oncology Institute Announces Resignation of Board Member Gabe Ling
The Oncology Institute, Inc. (NASDAQ: TOI) announced the resignation of board member Gabe Ling, effective December 1, 2025. A formal search has begun to find new independent directors who possess complementary expertise in healthcare and clinical care. The Chairman of the Board, Anne McGeorge, expressed gratitude for Ling's contributions during a pivotal time in the company's public market journey.
Read more →-TOI
Nov 14, 2025THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION ( L y 2 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION ~ Some of the information in this presentation is not historical in nature and may constitute forward - looking statements,
The Oncology Institute of Hope & Innovation is highlighting its forward-looking financial projections, anticipating significant revenue growth and a transition to EBITDA positive status by Q4 2025. The institute emphasizes its commitment to enhancing cancer care through an innovative value-based care model. Its ongoing expansion across various business channels aims to foster better patient outcomes while controlling costs. Furthermore, the institute is focusing on increasing its specialty pharmacy services to improve accessibility and reduce costs for patients.
Read more →-TOI
Nov 13, 2025The Oncology Institute Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
The Oncology Institute, Inc. reported strong third-quarter financial results for 2025, updating its revenue guidance upwards to reflect anticipated growth. The company's increase in full-year guidance is driven by robust operational performance and initiatives leveraging AI for efficiency. However, despite positive outlooks, TOI still faces challenges, notably projected losses in Adjusted EBITDA and potential market risks arising from tariffs and exchange rates. The CEO expressed a commitment to maintaining high-quality, value-based cancer care while managing costs.
Read more →-TOI
Aug 13, 2025The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance
The Oncology Institute, Inc. (TOI) reported a strong second quarter for 2025, with over 20% year-over-year revenue growth driven primarily by its pharmacy segment which saw growth exceeding 40%. The company is expanding its partnerships to double the lives covered in Florida, which augments its growth potential. Despite positive signs, challenges remain, such as projected negative Adjusted EBITDA in the near term and external economic risks that could affect operations. Overall, TOI reaffirms its guidance for the year, indicating a robust outlook for revenue and operational performance.
Read more →-TOI
Aug 13, 2025The Oncology Institute Announces Changes to Board of Directors Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New Chairman
The Oncology Institute announced the retirement of Chairman Richard Barasch, effective August 12, 2025, and the appointment of Anne McGeorge as the new Chairman. McGeorge, who has over 35 years of experience in healthcare finance, is set to bring valuable expertise to the board after serving as a member and chair of the Audit Committee. Richard Barasch expressed confidence in her abilities and highlighted the significant progress TOI made under his leadership. The transition aims to ensure continued advancement in the institute's mission of delivering high-quality oncology care.
Read more →-TOI
May 19, 2025THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION May 2025 This presentation is being furnished solely for the purpose of considering a potential private placement of securities (the PIPE Financing) involving The Oncology Inst
The Oncology Institute of Hope & Innovation is presenting information for a potential private placement of securities aimed at attracting investors. This opportunity comes amidst an expanding oncology market, driven by increasing complexities in clinical pathways and high drug costs. The presentation emphasizes TOI's innovative healthcare delivery model, which integrates patient care with cost management strategies. Despite the potential benefits outlined, the document includes disclaimers about the risks and uncertainties involving forward-looking statements.
Read more →-TOI
May 14, 2025The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance
The Oncology Institute (TOI) announced its financial results for the first quarter of 2025, reporting a revenue increase of 10.3% year-over-year to $104.4 million. The CEO emphasized strong progress driven by operational management and market expansion, with plans for sustained profitability in 2026. The company reaffirmed its full year guidance of $460 to $480 million in revenue, despite projecting an Adjusted EBITDA loss. TOI's services received positive feedback, contributing to its growth momentum.
Read more →-TOI
Mar 24, 2025The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025
The Oncology Institute (TOI) reported its financial results for Q4 and the full year of 2024, showing a revenue increase of 21.3% year-over-year. The company achieved positive cash flow for the second consecutive quarter and experienced significant growth in its dispensary operations. However, TOI faced challenges with a net loss of $13.2 million for Q4 and anticipated ongoing financial struggles reflected in its 2025 guidance. The firm is committed to operational efficiency as it navigates these challenges.
Read more →-TOI
Mar 24, 2025THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Q February 2025 2 THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION % This presentation is being furnished solely for the purpose of considering a potential private placement of secu
The Oncology Institute is considering a potential private placement of securities to attract investment. This move highlights the growing oncology market, which is driven by increasing healthcare expenditures and a rising incidence of chronic illnesses. However, the company emphasizes that the financial information provided is preliminary and should not be solely relied upon for investment decisions. Additionally, they express no guarantees regarding the accuracy of the data presented, which could be subject to changes and various risks.
Read more →-TOI
Mar 24, 2025The Oncology Institute Announces $16.5 million Private Placement
The Oncology Institute has announced a private placement expected to raise approximately $16.5 million from accredited investors. This placement will involve the issuance of common stock and warrants, with a closing date set for March 26, 2025. The proceeds are intended to support the company's organic growth and working capital. The transaction is backed by existing investors, including Deerfield Management Company, which will exchange a portion of its convertible notes for preferred stock and warrants in the company.
Read more →-TOI
Feb 26, 2025The Oncology Institute Announces Amendment to Facility Agreement and Debt Paydown
The Oncology Institute (TOI) has announced an amendment to its facility agreement with Deerfield Management, which includes the waiver of certain restrictions and the removal of a minimum cash requirement. Additionally, TOI has paid down approximately $20 million of its senior secured convertible notes. This financial adjustment is expected to strengthen TOI's financial stability and support its growth initiatives, including signing new capitation agreements in multiple states. The company aims to accelerate its impact in the oncology sector with these changes.
Read more →-TOI
Sep 23, 2024The Oncology Institute Announces CFO Transition Rob Carter promoted to Chief Financial Officer
The Oncology Institute announced a leadership transition with Rob Carter being promoted to Chief Financial Officer, effective October 14, 2024. He succeeds Mihir Shah, who will leave the organization to pursue other opportunities. Carter brings over a decade of finance experience from notable healthcare institutions and has already contributed significantly to TOI since joining in 2021. CEO Dr. Daniel Virnich has expressed confidence in Carter's ability to lead the finance operations during the next phase of TOI's growth.
Read more →-TOI
Jun 12, 2023toitransitionpress 6/9/23, 1:42 PM the-oncology-institute-announces-leadership-transition https://prdesk.globenewswire.com/JobPreview/PnrArticlePreview?t=5640719&l=eng 1/2 The Oncology Institute Announces Leadership Tran
The Oncology Institute (TOI) announced a leadership transition where Dr. Daniel Virnich will succeed Brad Hively as CEO effective June 30, 2023. Hively will move to the role of Vice Chairman, focusing on strategic partnerships and governance. Dr. Virnich, a significant figure in TOI's growth, expressed his commitment to advancing the company's mission in delivering specialized cancer care. This transition is seen as a strategic move to enhance TOI's position in the oncology landscape while reflecting on Hively's contributions to the company's development.
Read more →-TOI
Aug 9, 2022Document The Oncology Institute announces $110 million strategic investment by Deerfield Management to accelerate its expansion into new markets Investment to accelerate Company's expansion into new markets, bringing hig
The Oncology Institute announces $110 million strategic investment by Deerfield Management to accelerate its expansion into new markets Investment to accelerate Company's expansion into new markets, bringing high-quality, value-based care to more patients CERRITOS, Calif., Augu
Read more →-TOI
Mar 11, 2022toiinvestorpr Investor Presentation March 2022 We are a Leading Value Based Oncology Care Platform 2 160+ Clinical Trials Giving Patients Cutting Edge Treatment Access ~51K Unique Patient Encounters in 2021 Who We Are Re
Investor Presentation March 2022 We are a Leading Value Based Oncology Care Platform 2 160+ Clinical Trials Giving Patients Cutting Edge Treatment Access ~51K Unique Patient Encounters in 2021 Who We Are Relationships with Leading Payors and Risk Taking Providers Our Growth (Rev
Read more →-TOI
Nov 18, 2021TOI Parent, Inc. Table of Contents Financial Statements 2 Condensed Consolidated Balance Sheets (Unaudited) 3 Condensed Consolidated Statements of Operations (Unaudited) 4 Condensed Consolidated Statements of Convertible
Financial Statements 2 Condensed Consolidated Balance Sheets (Unaudited) 3 Condensed Consolidated Statements of Operations (Unaudited) 4 Condensed Consolidated Statements of Convertible Preferred Shares and Changes in Stockholders' Deficit (Unaudited) 5 Condensed Consolidated Sta
Read more →-TOI
Nov 15, 2021GlobeNewswire COVID-19 NEWS SERVICESv CONTACT us FRAN ,;AIS SIGN IN by notified f w in ~ The Oncology Institute Completes Business Combination with DFP Healthcare Acquisitions Corp. to Become Publicly-Traded Company
Explore Finnish TamP-ere Deck Arena is now Nokia Arena .. : ., . - GlobeNewsw1 re by notified About Us ~ CNt INDUSTRIAL SUSTAINABILITY LEADER CNH Industrial maintains its tOP P-Osition in the ... GlobeNewswire is one of the world's largest newswire distribution networks, speciali
Read more →-TOI
Oct 22, 2021DFP Healthcare Acquisitions Corp. Announces Special Meeting Date to Approve Proposed Business Combination with The Oncology Institute Special Meeting of Stockholders Scheduled for
DFP Healthcare Acquisitions Corp. Announces Special Meeting Date to Approve Proposed Business Combination with The Oncology Institute Special Meeting of Stockholders Scheduled for NEW YORK, October 22, 2021 -- DFP Healthcare Acquisitions Corp. ("DFP") (Nasdaq: DFPH) announc
Read more →-TOI
Oct 12, 2021The Leader in Value Based Oncology Care October 2021 Analyst Day Presentation Disclaimer and Forward Looking Statements 2 Disclaimer: This presentation is provided for informational purposes only and has been prepared to
The Leader in Value Based Oncology Care October 2021 Analyst Day Presentation Disclaimer and Forward Looking Statements 2 Disclaimer: This presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation w
Read more →-TOI
Jun 28, 2021DFP Healthcare Acquisitions Corp. ANNOUNCES PROPOSED BUSINESS COMBINATION WITH the oncology institute The Oncology Institute is the U.S. Market Leader in Value-Based Oncology Care New York, NY and L
Healthcare Acquisitions Corp. ANNOUNCES PROPOSED BUSINESS COMBINATION WITH the oncology institute The Oncology Institute is the U.S. Market Leader in Value-Based Oncology Care New York, NY and Los Angeles, CA - June 28, 2021 - DFP Healthcare Acquisitions Corp ("DFP") (NASDAQ:
Read more →-TOI
May 1, 2020DFP Healthcare Acquisitions Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about
Healthcare Acquisitions Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about May 1, 2020 YORK, April 28, 2020 - DFP Healthcare Acquisitions Corp. (the "Company") announced today that holders of the units sold in the Company's in
Read more →-TOI
Mar 13, 2020DFP HEALTHCARE ACQUISITIONS CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 Report of Independent Registered Public Accounting Firm To the Stockholders and t
HEALTHCARE ACQUISITIONS CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 of Independent Registered Public Accounting Firm and the Board of Directors of on the Financial Statement the accompanying balance sheet of
Read more →-TOI
Mar 10, 2020DFP Healthcare Acquisitions Corp. Announces Pricing of $200 Million Initial Public Offering
Acquisitions Corp. Announces Pricing of $200 Million Initial Public Offering 10, 2020 - DFP Healthcare Acquisitions Corp. (the "Company") announced today the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. The units will be listed on Th
Read more →Competitive Position
How TOI ranks across every disease it competes inCompetitive Position is a premium feature
See how TOI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial